Live Stock Coverage: Could AstraZeneca plc (ADR) Crash Even More? The Stock Just Made Yearly Low

Live Stock Coverage: Could AstraZeneca plc (ADR) Crash Even More? The Stock Just Made Yearly Low

The stock of AstraZeneca plc (ADR) (NYSE:AZN) hit a new 52-week low and has $25.02 target or 3.00% below today’s $25.79 share price. The 6 months bearish chart indicates high risk for the $63.34 billion company. The 1-year low was reported on Dec, 1 by Barchart.com. If the $25.02 price target is reached, the company will be worth $1.90B less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 9.00M shares traded hands or 18.58% up from the average. AstraZeneca plc (ADR) (NYSE:AZN) has declined 10.69% since April 28, 2016 and is downtrending. It has underperformed by 16.62% the S&P500.

Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on February, 2. They expect $0.57 earnings per share, down 39.36% or $0.37 from last year’s $0.94 per share. AZN’s profit will be $1.40B for 11.31 P/E if the $0.57 EPS becomes a reality. After $1.32 actual earnings per share reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -56.82% negative EPS growth.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 18 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 12 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 67% are positive. AstraZeneca plc (ADR) has been the topic of 21 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating by Piperjaffray given on Friday, September 23. The firm has “Hold” rating by Nordea given on Monday, November 2. The stock of AstraZeneca plc (ADR) (NYSE:AZN) has “Underperform” rating given on Tuesday, October 20 by Credit Suisse. The rating was upgraded by Oddo & Cie on Tuesday, January 26 to “Top Pick”. HBSC downgraded the shares of AZN in a report on Monday, February 8 to “Hold” rating. As per Friday, November 25, the company rating was upgraded by Liberum Capital. HSBC upgraded AstraZeneca plc (ADR) (NYSE:AZN) on Wednesday, September 2 to “Buy” rating. The stock has “Buy” rating given by Cantor Fitzgerald on Friday, February 26. The firm has “Buy” rating given on Friday, September 18 by Bryan Garnier & Cie. The firm earned “Buy” rating on Friday, July 31 by Swedbank.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

Another recent and important AstraZeneca plc (ADR) (NYSE:AZN) news was published by Businessfinancenews.com which published an article titled: “AstraZeneca plc (ADR): What Are the Future Prospects?” on August 01, 2016.

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment